Table 1.
Clinical features in Black versus non-Black men with hormone-sensitive metastatic prostate cancerab.
| Overall N = 74 | Non-Black n = 51 (69%) | Black n = 23 (31%) | p value | |
|---|---|---|---|---|
| Age at diagnosis (yr), median (IQR) | 71 (63–79) | 71 (63–81) | 70 (65–75) | 0.9441 |
| <65 yr, n (%) | 23 (31) | 16 (31) | 7 (30) | 1.000 |
| ≥65 yr, n (%) | 51 (69) | 35 (69) | 16 (70) | |
| Married, n (%) | 43 (58) | 33 (65) | 10 (44) | 0.2969 |
| Insurance, n (%) (n = 73) | 0.3203 | |||
| Private | 41 (56) | 29 (58) | 12 (52) | |
| Public | 31 (43) | 21 (42) | 10 (44) | |
| Smoking status, n (%) (n = 72) | 0.4024 | |||
| Current | 3 (4) | 1 (2) | 2 (9) | |
| Former | 40 (56) | 28 (56) | 12 (55) | |
| Never | 29 (40) | 21 (42) | 8 (36) | |
| Body mass index (kg/m2), median (IQR) (n = 71) | 27.6 (24.8–31.1) | 28.3 (25.2–31.0) | 26.3 (22.5–32.8) | 0.5907 |
| ECOG at diagnosis, n (%) | 0.0589 | |||
| 0 | 59 (80) | 44 (86) | 15 (65) | |
| ≥1 | 15 (20) | 7 (14) | 8 (35) | |
| Baseline PSA (ng/mL), median (IQR) (n = 51) | 110 (35–677) | 81 (22–403) | 304 (53–1402) | |
| Gleason score, n (%) | 0.1736 | |||
| 7 | 27 (36) | 16 (31) | 11 (48) | |
| 8–10 | 47 (64) | 35 (69) | 12 (52) | |
| Total distant metastases, median (IQR) | 1 (1-2) | 1 (1-2) | 2 (1-2) | 0.8065 |
| Bone metastases, n (%) | 56 (76) | 39 (76) | 17 (74) | 1.000 |
| Laboratory values, median (IQR) | ||||
| Hemoglobin (g/dL) (n = 71) | 12.5 (11.0–13.69) | 13.0 (11.5–13.9) | 11.1 (8.6–13.7) | 0.0408 |
| Lymphocytes (109 cells/liter) (n = 65) | 1.4 (1.0–1.8) | 1.3 (1.0–1.8) | 1.6 (1.2–1.8) | 0.5270 |
| Creatinine (mg/dL) (n = 73) | (1.10.05)(0.9–1.6) | 1.1 (0.9–1.4) | 1.5 (1.1–1.7) | 0.0454 |
| ALT (U/L) (n = 70) | 21 (15–27) | 21 (15–29) | 18 (15–22) | 0.2722 |
| ALP (U/L) (n = 70) | 95 (68–229) | 89 (65–216) | 117 (73–412) | 0.4456 |
| Albumin (g/dL) (n = 70) | 3.6 (3.4–4.1) | 3.7 (3.5–4.2) | 3.4 (3.1–3.6) | 0.0055 |
| Comorbid conditions, median (IQR) | 2 (1–3) | 2 (1–3) | 2 (2-3) | 0.4455 |
| History of diabetes, n (%) | 21 (28) | 11 (22) | 10 (43) | 0.0530 |
| Presenting symptoms, n (%) | ||||
| None | 7 (9) | 7 (14) | 0 (0) | 0.0912 |
| Fatigue | 11 (15) | 6 (12) | 5 (22) | 0.3008 |
| Hematuria | 18 (24) | 12 (23) | 6 (26) | 0.8124 |
| Lower urinary tract | 45 (61) | 32 (63) | 13 (57) | 0.6118 |
| Pain | 28 (38) | 18 (35) | 10 (43) | 0.5017 |
| Weight loss | 21 (28) | 11 (22) | 10 (43) | 0.0530 |
| Frontline docetaxel, n (%) | 25 (34) | 18 (35) | 6 (26) | 0.4336 |
| Progression, n (%) (n = 62)c | 34 (55) | 26 (60) | 8 (44) | 0.2928 |
| Died, n (%) (n = 66) | 36 (55) | 26 (56) | 10 (50) | 0.6248 |
aALT = alanine aminotransferase, ALP = alkaline phosphatase, ECOG = European Cooperative Oncology Group; IQR = interquartile range, and PSA = prostate-specific antigen. bMedian follow-up for all patients 23.3 (13.4–35.0), Black 18.9 (11.8–36.5), and non-Black 24.7 (14.6–35.0) in months. cSample less than 74 as progression status was unknown for 12 men.